Screener Summaries Updates Institutions Sign In More Updates › Mergers & Acquisitions › ILMN Mergers & Acquisitions · Jan 30, 2026
Illumina, Inc. has completed the acquisition of Standard BioTools Inc.’s aptamer-based and functional proteomics… ILMN Illumina, Inc.
Illumina, Inc. has completed the acquisition of Standard BioTools Inc.’s aptamer-based and functional proteomics business, including SomaLogic, Inc. and Sengenics Corporation. The company paid a $350 million cash purchase price, with the agreement also providing for up to $75 million in potential milestone payments.
More from Illumina, Inc. Illumina reports Q3 revenue of $1.13 billion, raises full-year guidance Oct 29, 2026 Illumina establishes $1.0 billion unsecured commercial paper program Oct 13, 2026 On August 17, 2026, Illumina completed a public offering of $300 million aggregate principal amount of its 4.950%… Aug 17, 2026 Illumina, Inc. entered into a new $1,000 million senior unsecured five-year revolving credit facility on August 13… Aug 13, 2026 On August 10, 2026, Illumina entered into an underwriting agreement to issue and sell $300 million in aggregate… Aug 12, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
